Table 2.
Characteristics of CD patients enrolled in ultrastructural studies.
| No of Patient |
Sex | Age [in Years] |
The Level of Anti-tTG2-IgA/[AU/mL] | Histology | Diagnosis |
|---|---|---|---|---|---|
| 1. | Male | 8 | 10 | Marsh 0 | Potential CD |
| 2. | Male | 7 | 19 | Marsh 1 | Potential CD |
| 3. | Female | 6 | 24 | Marsh 1 | Potential CD |
| 4. | Female | 10 | 31 | Marsh 2 | Active CD |
| 5. | Male | 7 | 54 | Marsh 3a | Active CD |
| 6. | Male | 7 | >100 | Marsh 3b | Active CD |
| 7. | Female | 14 | >100 | Marsh 3b | Active CD |
| 8. | Female | 10 | >100 | Marsh 3b | Active CD |
| 9. | Male | 9 | >100 | Marsh 3b | Active CD |
| 10. | Male | 9 | Negative* | Marsh 3b | Active CD |
| 11. | Male | 6 | >100 | Marsh 3b | Active CD |
| 12. | Female | 3 | >100 | Marsh 3c | Active CD |
Histological changes were determined using the modified Marsh-Oberhuber classification. The active CD was recognized in accordance with the ESPGHAN 2012 guidelines. *Patient No. 10 had IgA deficit and positive anti-tTG2-IgG (>100 AU/mL). All patients with potential CD (patients No. 1, 2, 3) had positive anti-EMA-IgA antibodies in the following titers 1: 5, 1:50, 1: 5, respectively.